Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101

Executive Summary

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

You may also be interested in...



Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China

With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.

Dermira Wins First FDA Approval, Preps Qbrexza For October Launch In Hyperhidrosis

The company shifted attention in March from its big acne setback to its mid-year Qbrexza approval, so with a recent FDA nod for the hyperhidrosis treatment, Dermira will fill out its sales team and make the topical product for excessive underarm sweating available in October.

Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel